Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/728041	
- IN	IFORMATION	I DI	SCLOSURE	Filing Date	December 3, 2003	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Samuel J. Danishefsky	
				Art Unit	1643	
(Use as many sheets as necessary)			necessary)	Examiner Name	Karen A. Canella	
Sheet	1	of	5	Attorney Docket Number	2003080-0142(SK-893-B)	

U.S. PATENT DOCUMENTS										
	Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where									
Examiner Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear					
	A1	US-09/276,595								
	A2	US-09/641,742								
	A3	US-09/083,776								
	A4*	US-RE38,04		Longenecker et al.						
	A5*	US-5,977,081	11-02-1999	Marciani						
	A6*	US-6,080,725	06-27-2000	Marciani						
	A7*	US-6,090,789	07-18-2000	Danishefsky et al.						
	A8*	US-20020006900	01-17-2002	Danishefsky et al.						
	A9*	US-6,355,639	03-12-2002	Chou et al.						
	A10*	US-20020038017	03-28-2002	Danishefsky et al.						
	A11*	US-6,548,661	04-15-2003	Danishefsky et al.						
	A12*	US-20030153492	08-14-2003	Danishefsky et al.						
	A13*	US-6,660,714	12-09-2003	Danishefsky et al.						
	A14*	US-20040208884	10-21-2004	Danishefsky et al.						
	A15*	US-7,018,637	03-28-2006	Chong et al.						
	A16*	US-7,160,856	01-09-2007	Danishefsky et al.						
	A17*	US-7,531,181	05-12-2009	Danishefsky et al.						
	A18*	US-7,550,146	06-23-2009	Danishefsky et al.						
	A19*	US-7,635,750	12-22-2009	Danishefsky et al.						
		US-7,645,454	01-12-2010	Danishefsky et al.						
	A21*	US-20100081786	04-01-2010	Danishefsky et al.						

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶		
	B1	EP-315153-A2	05-10-1989	Syntex Inc		Г		
	B2	WO-9852573-A1	11-26-1998	Galenica Pharmaceuticals Inc et al.				
	B3	WO-9915201-A1	04-01-1999	Sloan Kettering Inst Cancer et al.				
	B4	WO-9948515-A1	09-30-1999	Sloan Kettering Inst Cancer		Г		
	B5	WO-01065261-A1	09-07-2001	Sloan Kettering Inst Cancer		Г		
	В6	WO-04011476-A1	02-05-2004	Sloan Kettering Inst Cancer et al.		Г		
	В7	WO-04050711-A2	06-17-2004	Sloan Kettering Inst Cancer et al.		г		
	В8	WO-0460915-A2	07-22-2004	Sloan Kettering Inst Cancer et al.		Г		
	B9	WO-10006343-A2	01-14-2010	Sloan Kettering Inst Cancer et al				

EXAMANES: Initial inference considered, whether or not distinct is a conformer on the MED 500. Date the through distinct if not in conformation and not considered. Include copy of this form with next communication to applicant. *CTRN 10%. These application(wheth wheth are interested when a region selection to the Clo No. are not supplied (under 37 CFR 1.98(a)/2(iii)) because that application was fleed after June 30, 2000 or is available in the TIPN. *Applicantion number (positions) "See Rivide Code of USPTO* Patter Occuments at a grow_cate_grow of MEP 500 A.** Elect of filter better under contract the conformation of the conformation

4665073v	/Karen A. Canella, Ph.D./	Date Considered	06/07/2010
1	,,	Considered	00/01/2010

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/728041	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	December 3, 2003	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Samuel J. Danishefsky	
				Art Unit	1643	
(Use as many sheets as necessary)				Examiner Name	Karen A. Canella	
Sheet	2	of	5	Attorney Docket Number	2003080-0142(SK-893-B)	

		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	and/or country where published.							
	C1	Allen et al. "Pursuit of optimal carbohydrate-based anticancer vaccines: preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and Lewis" antigens", J. Am. Chem. Soc. 123:1890-1897. 2001.							
	C2	Anderson, P. (1983) Infection & Immunity 39, 233-238	_						
	C3	Bachman, et al. Journal of Immunology, 2005, Vol. 175, pp. 4677-4685							
	C4	Barington, T. et al. (1993) Infect. Immun. 61, 432-438							
	C5	Barington, T. et al. (1994) Infection & Immunity 62, 9-14							
	C6	Bilodeau et al. J. Am. Chem. Soc. 1995, 117, 7840-7841							
	C7	Bischoff, et al. International Archives of Allergy and Applied Immunology, 1984, Vol. 75, pp. 20-26 (abstract only)							
	C8	Biswas et al. "Construction of carbohydrate-based antitumor vaccines: synthesis of glycosyl amino acids by olefin cross-metathesis", Tetrahedron Letters, 43:6107-6110, 2002							
	C9	Blackwell et al. "New approaches to olefin cross-metathesis", J. Am. Chem. Soc., 122:58-71, 2000							
	C10	Bosse et al. "Linear synthesis of the tumor-associated carbohydrate antigens Globo-H, SSEA-3, and Gb3", J. Org. Chem., 67:6659-6670, 2002							
	C11	Brezicka et al. Cancer Res. 1989, 49, 1300-1305							
	C12	Brocke, C. et al. Bioorg. & Med. Chem. 2002, 10, 3085-3112							
	C13	Burk et al. Accts. Chem. Res. 2000, 33, 363-372							
	C14	Burk et al. Pure & Appl. Chem. 1996, 68, 37-44							
	C15	Catelani et al. Carb. Res. 1988, 182, 297-300							
	C16	Chappell et al. Tetrahedron 1997, 53, 11109-11120							
	C17	Chen et al. J. Am. Chem. Soc. 1998, 120, 7760-7769							
	C18	Cross, A. M. et al. (1994) Journal of Infectious Diseases 170, 834-840							
	C19	D. M. Coltart et al. "Principles of Mucin Architecture: Structural Studies on Synthetic Glycopeptides Bearing Clustered Mono-, Di-, Tri- and Hexasaccharide Glycodomains" J. Am. Chem. Soc. (2002) 124, 9833-9844							
	C20	Danishefsky et al. J. Am. Chem. Soc. 1995, 117, 5701-5711							
	C21	Danishefsky, S. J. et al. Angew. Chem., Int. Ed. Engl. 1996, 35, 1380-1419							
	C22_	Dasgupta et al. Carbohydr. Res. 1994, 264, 155-160							
	C23	Database BIOSIS'Onlinel Biosciences Information Service, Philadelphia, PA, US; 22 March 2002, Kovbasnjuk Olga et al., "Glycosphingolipid Gba as biomarker for invasive colon carcinoma cells", FASEB Journal, 14(5):A1200, 2002, Annual Heeling of Professional Research Scientists on Experimental Biology; New Orleans, LA, USA, April 20-24, 2002							
	C24_	David et al. J. Chem. Soc. Perkin Trans. I 1981, 1796-1801							
	C25	Dranoff et al. Proc. Natl. Acad. Sci, USA 1993, 90, 3539-3543							
	C26_	Efferson, et al. Anticancer Research, 2005, Vol. 25, pp. 715-724							
	C27	Fattom, A. et al. (1999) Vaccine 17, 126-133							
	C28	Ferezou, et al. Nutrition, 2001, Vol. 17, pp. 930-933	Ĺ						
	C29	Fraser-Reid et al. 1990, 55, 6068-6070							
	C30	Fung, P. et al. Cancer Res. 1990, 50, 4308-4314							
	C31	Furstner, A. Angew. Chem., Int. Ed. Engl. 2000, 39, 3013-3043							
	C32	Garegg, P.J. Pure Appl. Chem. 1984, 56, 845-858	L						

4665073v 1	/Karen A. Canella, Ph.D./	Date Considered	06/07/2010

Sul	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/728041	
l II	VEORMATION	1 DI	SCLOSURE	Filing Date	December 3, 2003	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Samuel J. Danishefsky	
				Art Unit	1643	
	(Use as many sh	eets as	s necessary)	Examiner Name	Karen A. Canella	
Sheet	3	of	5	Attorney Docket Number	2003080-0142(SK-893-B)	

C33 Gatza, et al. Journal of Immunology, 2002, Vol. 169, pp. 5227-5255			Tarrick Communication of the c						
C35 Glunz, P. W. et al. J. Am. Chem. Soc. 1999, 121, 10636-10637 and 14186									
C36 Gordon et al. Carbohydrale Res. 1990, 206, 381-386 C37 Grazi, et al. Bichohemical and Biophysical Research Communications, 1960, Vol. 2, pp. 121-125 (abstract only) C38 Griffith et al. J. Am. Chem. Soc. 1990, 112, 5811-5819 C39 Griffith et al. J. Am. Chem. Soc. 1991, 113, 5883-5864 C40 Hakomori, S. Adv. Cancer Res. 1999, 52, 257-331 C41 Hakomori, S. Adv. Cancer Res. 1999, 52, 257-331 C42 Heilling, F. et al. (1994) Cancer Research 54, 197-203 C43 Heilling, F. et al. (1994) Cancer Res. 50, 2183-2190 C44 Heilling, F. et al. (1994) Cancer Res. 50, 2183-2190 C44 International Search Report for PCTI/US00/022989 mailed April 10, 2001 C45 International Search Report for PCTI/US00/022989 mailed April 10, 2001 C46 International Search Report for PCTI/US00/040253 mailed October 18, 2005 C47 Jannson et al. J. Grg. Chem. 1998, 33, 5629-9847 C48 Jannson et al. J. Grg. Chem. 1998, 33, 5629-9847 C49 Kanra, G. et al. (1998) Vaccine 16, 109-113 C49 Kanra, G. et al. (2000) Vaccine 18, 947-954 C50 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kadar and Klien, "Cancer immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding et al. "Hydroxynorisucine as a glycosy acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 702-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH Longuates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1996, 80, 7716-7717 Kim et al. J. Org. Chem. 1996, 90, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C61 Kudryashov et alTencar optimized carbohydrate-base									
C37 Grazi, et al. Biochemical and Biophysical Research Communications, 1960, Vol. 2, pp. 121-125 (abstract only) C38 Griffith et al. J. Am. Chem. Soc. 1990, 112, 5811-5819 C39 Griffith et al. J. Am. Chem. Soc. 1990, 112, 5811-5819 C39 Griffith et al. J. Am. Chem. Soc. 1990, 112, 5818-5864 C40 Hakomori, S. Adv. Cancer Res. 1999, 52, 257-331 C41 Hakomori, S. Adv. Cancer Res. 1999, 52, 257-331 C41 Helling, F. et al. (1994) Cancer Research 54, 197-203 C43 Hellitorn, I. et al. (1995) Cancer Research 54, 197-203 C44 Helling, F. et al. (1994) Cancer Research 54, 197-203 C45 International Search Report for PCTI/US2000022894 mailed April 10, 2001 C46 International Search Report for PCTI/US2000022894 mailed April 10, 2005 C47 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C48 Jones, I. G. et al. (1998) Vaccine 16, 109-113 C49 Kanra, G. et al. (2000) Vaccine 18, 947-954 Kanra, G. et al. (2000) Vaccine 18, 947-954 Koawai et al. Chem. Lett. 1990, 577-580 C51 Kadar and Kilen, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Kading and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kading et al. "Hydroxynorioucine as a glycosy acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C56 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C57 Kim et al. J. Grg. Chem. 1998, 69, 716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C57 Kim et al. J. Grg. Chem. 1998, 69, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudyashov et al. Toward optimized carbohydrate-based anticancer vaccines: Epilope clustefing, carrier structure, and adjuvant al influence antibod				0637 and 1418	6				
125 (abstract only)									
C39 Griffith et al. J. Am. Chem. Soc. 1991, 113, 5863-5864	ľ	C37	125 (abstract only)	unications, 196	60, Vol. 2, pp. 121-				
C40		C38	Griffith et al. J. Am. Chem. Soc. 1990, 112, 5811-5819						
C41 Hakomorf, S. et al. Chem. Biol. 1997, 4, 97-104 C42 Helling, F. et al. (1994) Cancer Research 54, 197-203 C43 Helling, F., et al. (1994) Cancer Research 54, 197-203 C44 Hellistorm, I. et al. (1990) Cancer Res. 50, 2185-2190 C44 International Search Report for PCTIVS2000022894 mailed December 10, 2003 C45 International Search Report for PCTIVS2000022894 mailed April 10, 2001 C46 International Search Report for PCTIVS2000022894 mailed April 10, 2005 C47 Jannson et al. J. Org. Chem. 1988, 35, 5629-984 C48 Jannson et al. J. Org. Chem. 1988, 35, 5629-984 C49 Jannson et al. J. Org. Chem. 1988, 35, 5629-984 C50 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kader and Klicin, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 Kading et al. "Hydroxynofreucline as a glycosyl acceptor is an efficient means for introducing amino acid functionally into complex carbohydrates", Tetrahedron Letters, 44,3413-3416, 2003 C55 Keding and Limitary and the complex carbohydrates, Tetrahedron 1991, 431-437 C56 Kim et al. "Effect of immunologi		C39	Griffith et al. J. Am. Chem. Soc. 1991, 113, 5863-5864						
C42 Helling, F. et al. (1994) Cancer Research 54, 197-203 C43 Hellstrom, I. et al. (1990) Cancer Res. 50, 2183-2190 C44 International Search Report for PCT/US2000/022894 mailed April 10, 2003 C45 International Search Report for PCT/US2000/022894 mailed April 10, 2001 C46 International Search Report for PCT/US2000/022894 mailed April 10, 2001 C47 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C48 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C49 Janes, I. G. et al. (1998) Vaccine 16, 109-113 C49 Kanra, G. et al. (2000) Vaccine 18, 947-954 C50 Kawai et al. Chem. Lett. 1990, 577-560 C51 Kedar and Klein, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding et al. "Hydroxyndresucine as a glycosy acceptor is an efficient means for introducing armino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Kedings, S. J. et al., Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH C		C40	Hakomori, S. Adv. Cancer Res. 1989, 52, 257-331						
C43 Hellstorm, I. et al. (1990) Cancer Res. 50, 2183-2190 C44 International Search Report for PCT/US200022884 mailed December 10, 2003 C45 International Search Report for PCT/US2000122884 mailed April 10, 2001 C46 International Search Report for PCT/US2000122884 mailed April 10, 2001 C47 Jannson et al. J. Org. Chem. 1998, 53, 5529-5847 C48 Jannson et al. J. Org. Chem. 1998, 53, 5529-5847 C49 Jannson et al. J. Org. Chem. 1998, 53, 5529-5847 C49 Jannson et al. J. Org. Chem. 1998, 53, 5529-5847 C49 Jannson et al. J. Org. Chem. 1998, 53, 5529-5847 C49 Jannson et al. Chem. Lett. 1990, 577-580 C50 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kadra and Klien, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Kading and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kading et al. "Hydrovynorleucine as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensal, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-Kt.1 and GD3-Kt.1 conjugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1995, 69, 716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Cancer Res. 1988, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1994, 95, 291-350-369, 2001 C61 Kudrysshov et al. Cancer Immunol. Immunother, 1998, 45, 231-236 C63 Kudrysshov et al. Cancer Immunol. Immunother, 1998, 45, 231-236 C64 Kudrysshov et al. J. Amc. Chem. Soc. 1998, 120, 12474-12485 C65 Kurlks, S. Cet al. J. Amc. Chem. Soc. 1998, 120, 12474-12485 C66 Kurlysskov, V. et al. (1998) Oyccoonigate Journal 15, 243-249 C67 Lanzavechis, Science, 1993, 269, 357-944 C68 Livingston et al. J. Cinn. Chem. Soc. 1998, 199, 745-7500 C70 Livingston et al. J. Cinn. Chem. Soc. 1998, 197, 197, 45, 10-19 C7		C41	Hakomori, S. et al. Chem. Biol. 1997, 4, 97-104						
C44 International Search Report for PCT/US03/22657 mailed December 10, 2003 C45 International Search Report for PCT/US03/2265284 mailed April 10, 2001 C46 International Search Report for PCT/US0200/026284 mailed April 10, 2001 C47 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C49 Jones, I. G. et al. (1989) Vaccine 18, 947-954 C49 Sharis, G. et al. (2000) Vaccine 18, 947-954 C50 Kawai et al. Chem. Lett. 1999, 677-560 C51 Kedar and Kilen, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding et al. "Hydroxynorfeucine as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and G93-KLH conjugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1996, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kieds, S. K. et al. (1900) Vaccine 18, 597-603 C59 Kim et al. J. Org. Chem. 1996, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 King S. et al. Tetrahedron 1993, 49, 5201-5304 Kudyashov et al. "Toward optimized carbohydrate-based articancer vaccines: Epitope distinction of the antibody and the control and carbohydrate-based articancer vaccines: Epitope Carbohydrate-based articancer vaccines:		C42	Helling, F. et al. (1994) Cancer Research 54, 197-203						
C45 International Search Report for PCT/US2000/022894 malted April 10, 2001 C46 International Search Report for PCT/US2000/4040233 mailed October 18, 2005 C47 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C48 Jones, I. G. et al. (1998) Vaccine 18, 947-954 C50 Kawra, G. et al. (2000) Vaccine 18, 947-954 C50 Kawra (1, Comp. Cancer Immunotherapy*, In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C51 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding et al. "Hydroxynorioucine as a glycosyl acceptor is an efficient means for introducing amimo acid functionality into complex carbohydrates*, Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-RL4 and GD3-RL4 Cortiquates*, Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 C58 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 C59 Kjeldsen, T. B. et al. Ca		C43	Hellstrom, I. et al. (1990) Cancer Res. 50, 2183-2190						
C46 International Search Report for PCT/US2004/040253 mailed October 18, 2005 C47 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C49 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C49 Jannson et al. J. Org. Chem. 1998, 53, 5629-5647 C49 Jannson et al. J. Org. Chem. 1998, 13, 5629-5647 C50 Kawair et al. Chem. Lett. 1999, 777-560 C51 Kedar and Kilen, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding et al. "Hydroxynorisucines as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and G03-KLH conjugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1996, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kiedsen, T. B. et al. Cancer Res. 1988, 48, 2214-2220 C60 Koemen et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudryashov et al. Toward optimized carbohydrate based anticancer vaccines: Epitope custering, certier structure, and adjuvant al influence antibody responses to lewis" conjugates in mice, Proc. Natl. Acad. Sci. USA, 98, 3364-3289, 2001 C62 Kudryashov, V. et al. (1999) Glycoconjugates Journal 15, 245-249 C63 Kudryashov, V. et al. (1999) Glycoconjugates Journal 15, 245-249 C64 Kudryashov, V. et al. J. Chem. Oncol., 1998, 120, 1588-1599 C67 Laravaechis, Science, 1993, 269, 397-944 C68 Livingston et al. J. Cinn. Chem. Soc. 1998, 120, 12474-12485 C69 Livingston et al. J. Cancer Res. 1998, 48, 94, 764-629 Livingston et al. J. Cancer Res. 1998, 47, 100-19, 45, 10-19 C72 Livingston, P. O. et al. Cancer Immunol. Immunolibrer. 1997, 45, 10-19		C44	International Search Report for PCT/US03/22657 mailed D	ecember 10, 2	003				
C47		C45	International Search Report for PCT/US2000/022894 maile	ed April 10, 200)1				
C47 Jannson et al. J. Crg. Chem. 1998, 53, 6829-5647 C48 Jones, I. G. et al. (1989) Vaccine 18, 947-954 C49 Kanra, G. et al. (2000) Vaccine 18, 947-954 C50 Kawai et al. Chem. Lett. 1990, 877-880 C51 Kawai et al. Chem. Lett. 1990, 877-880 C52 Keding and Banishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C54 Keding, and Lett. 1990, 19		C46	International Search Report for PCT/US2004/040253 mails	ed October 18.	2005				
C48 Jones, I. G. et al. (1988) Vaccine 16, 109-113 C49 Kamra, G. et al. (2000) Vaccine 18, 947-954 C50 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kawai et al. Chem. Lett. 1990, 577-580 C52 Kaderia and Kilen, "Cancer Immunoliberapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Kading and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kading et al. "Hydroxynorleucline as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carborhydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1:KLH and G03-KLH Conjugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 Kim et al. J. Org. Chem. 1995, 60, 7716-7718 C68 Kim, S. K. et al. Erterhaderon 1993, 49, 5291-5304 C61 Kudrysshov et al. "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis" conjugates in mice. Proc. Natl. Acad. Sci. USA, 98:3264-3269, 2001 C62 Kudrysshov et al. Cancer Immunol. Immunother, 1998, 45, 245-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 Kwon et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 Kwon et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 Kwon et al. J. Am. Chem. Soc. 1998, 140, 12474-12485 Kwon et al. J. Am. Chem. Soc. 1998, 140, 12474-12485 Kwon et al. J. Am		C47		,					
C49 Kanra, G. et al. (2000) Vaccine 18, 947-954 C50 Kanra et al. Chem. Lett. 1990, 277-580 C51 Kaster and Kilen, Cancer Immunotherapy*, In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Kesting and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kesting and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kesting and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C54 Kesting and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C55 Kesting, S. J. et al. "Flytroxynorlesucine as a glycosyl acceptor is an efficient means for introducing goods and complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C55 Kensill, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MCI-rLH: et al. C93-KLH conjugates", Vaccine, 19:539-537, 2001 C57 Kim et al. J. C7, Chem. 1995, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldssen, T. S. et al. Caroor Res. 1998, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudrysakhov et al. "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis* conjugates in mine*, Proc. Natl. Acad. Sci. U.SA, 98:3284-3299, 2001 C62 Kudrysakhov et al. Caroor Royal Caroor Immunol. Immunother. 1998, 48, 281-286 C65 Kudrysakhov, et al. (1998) (1998, 120, 12474-12485 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C67 Kurkka, S. (1996) Vaccine 11, 1239-1242 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzawechis, Science, 1993, 260, 93-944 C68 Livingston et al. J. Cancer Res. 1898, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1898, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunolther. 1997, 45, 10-19		C48							
C50 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kawai et al. Chem. Lett. 1990, 577-580 C51 Kader and Kliser, 'Cancer Immunotherapy', In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-5322 C52 Keding and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kading et al. 'Hydroxynofreucine as a glycosyl acceptor is an efficient means for introducing amino acid functionally into complex carbohydrates', 'Tetrahedron Letters, 44:3413-3416, 2003 C54 Kading, S. J. et al. 'Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. 'Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and G03-KLH conjugates', 'Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Cancer Res. 1998, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, S291-5304 C61 Kudryshov et al. 'Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewise' conjugates in mice', Proc. Natl. Acad. Sci. USA, 98,3284-3299, 2001 C62 Kudrysshov et al. Cancer Immunol. Immunother. 1998, 45, 281-286 C63 Kudrysshov, V. et al. (1998) (Spoconipusate Journal 15, 243-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 Kwon et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzavechis, Science, 1993, 250, 307-944 C68 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19									
C51 Kadar and Kilen, "Cancer Immunotherapy", In: Advances in Cancer Research, 1992, Vol. 59, pp. 245-322 C52 Kading and Danishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 C53 Kading et al. "Hydroxynofacules as a sphossy acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kanell, C. R. et al. (1991). Immunot. 146, 431-437 C56 Kanell, C. R. et al. (1991). Immunot. 146, 431-437 C57 Kim et al. "Effect of immunot. 146, 431-437 C57 Kim et al. J. Org. Chem. 1995, 80, 7716-7710 jugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1995, 80, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. S. et al. Cancer Res. 1986, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudryashov et al. "Ower of pelinized carbohytrate-based anticancer vaccines: Epilope clustefing, carrier structure, and adjuvant all influence antibody responses to lewis" conjugates in mice", Proc. Natl. Acad. Sci. U.SA, 98:3284-3299, 2001 C62 Kudryashov et al. Cancer Immunot. Immunother. 1998, 45, 281-289 C63 Kudryashov, et al. (1999) Special processing in mice", Proc. Natl. Acad. Sci. U.SA, 98:3284-3299, 2001 C65 Kudryashov, et al. (1999) Special processing in mice", Proc. Natl. Acad. Sci. U.Sa) Special processing in mice", Proc. Natl. Acad. Sci. U.Sa) Special processing in Cancer Immunot. Immunother. 1998, 45, 281-289 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Canzavechis, Science, 1993, 260, 397-944 C68 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunot. Immunother. 1997, 45, 10-19									
pp. 245-322 CS2 Keding and Denishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 Keding at Denishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 Keding at Denishefsky, PNAS, 2004, Vol. 101, pp. 11937-11942 Keding et al. "Hydroxynorleucine as a glycosyl acceptor is an efficient means for introducing smine acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Org, Chem. 1995, 60, 7716-7717 Kim et al. J. Chem. 1995, 19				n Cancer Rese	arch 1992 Vol 59				
C53 Kading et al. "Hydroxynorioucine as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-RL4 and GD3-RL4 Conjugates", Vaccine, 19:530-837, 2001 C57 Kim et al. J. Org, Chem. 1995, 60, 771-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Cancer Res. 1988, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudryashov et al. "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis* conjugates in mice", Proc. Natl. Acad. Sci. USA, 98:3264-3269, 2001 C62 Kudryashov et al. Cancer Immunol. Immunother, 1998, 45, 231-2366 C63 Kudryashov, V. et al. (1998) Glycoconjugate Journal 15, 243-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kurfika, S. (1996) Vaccine 14, 1239-1242 C66 Kwom et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C67 Lanzawechis, Science, 1993, 260, 937-944 C68 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		001		ii oanooi rese	ardi, 1552, Vol. 55,				
C53 Keding et al. "Hydroxynorleucine as a glycosyl acceptor is an efficient means for introducing amimo acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416, 2003 C54 Keding, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kensil, C. R. et al. (1991) J. Immunot. 146, 431-437 C56 Kensil, C. R. et al. (1991) J. Immunot. 146, 431-437 C57 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1+CH.1 and GD3-KLH cortiguates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Crg. Chem. 1995, 60, 771-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Cancer Res. 1988, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudryshov et al. "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis" conjugates in mice", Proc. Natl. Acad. Sci. USA, 98, 3284-3269, 2001 C62 Kudrysahov et al. Cancer Immunol. Immunother. 1998, 45, 281-296 C63 Kudrysahov, V. et al. (1999) Glycoconipugate Journal 15, 243-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kurfikka, S. (1996) Vaccine 14, 1239-1242 C66 Kwom et al. J. Am. Chem. Soc. 1998, 120, 1589-1599 C67 Lanzawochis, Science, 1993, 260, 937-944 C68 Livingston et al. J. Cancer Res. 1989, 48, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19									
C54 Kading, S. J. et al. Tetrahedron 2003, 59, 7023-7031 C55 Kanali, C. R. et al. (1991). Immon. 146, 431-437 C56 Kanali, C. R. et al. (1991). Immon. 146, 431-437 C57 Kim et al. "Effect of immunol side; al. al. (1991). Immon. 146, 431-437 C58 Kim et al. J. Org. Chem. 1995, 80, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Caroor Res 1986, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudryashov et al. "Toward optimized carbohytrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis" conjugates in mice, "Proc. Natl. Acad. Sci. U.SA, 98.3264-3269, 2001 C62 Kudryashov et al. Caroor Immunol. Immunother. 1998, 45, 281-286 C63 Kudryashov, V. et al. (1998) (1900-coni)igate lournal 15, 243-249 C64 Kudruk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Caro Lanzavechis, Science, 1993, 260, 937-944 C68 Livingston et al. J. Cancer Res. 1998, 49, 644-629 C69 Livingston et al. J. Cancer Res. 1998, 49, 704-67-050 C70 Livingston et al. J. Cancer Res. 1998, 49, 704-67-050 C71 Livingston, P. O. et al. Cancer Immunol. Immunoliner. 1997, 45, 10-19		C53	3 Keding et al. "Hydroxynorleucine as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates", Tetrahedron Letters, 44:3413-3416,						
C55 Kensil, C. R. et al. (1991) J. Immunol. 146, 431-437 C56 Klm et al. "Effect of Immunological adjuvent combinations on the antibody and T-cell response to vaccination with MUC1-KLH and G03-KLH conjugates", Vaccine, 19:530-537, 2001 C57 Klm et al. J. Grig. Chem. 1995, 60, 771-67717 C58 Klm, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Cancer Res. 1998, 48, 2214-2220 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C61 Kudryashov et al. "Toward oplimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis" conjugates in mice", Proc. Natl. Acad. Sci. USA, 98,3264-3269, 2001 C62 Kudryashov et al. Cancer Immunol. Immunother. 1998, 45, 281-286 C63 Kudryashov, V. et al. (1999) Glycoconjugate Journal 15, 243-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kurfikka, S. (1996) Vaccine 14, 1239-1242 C66 Kwom et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzawochis, Science, 1993, 260, 937-944 C68 Livingston et al. J. Cancer Res. 1998, 48, 7045-7050 C70 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		CEA							
C56 Kim et al. "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates", Vaccine, 19:530-537, 2001 C57 Kim et al. J. Org. Chem. 1995, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 507-603 C59 Kight St. et al. (2000) Vaccine 18, 507-603 C60 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C81 Kudyashov et al. Toward optimized carbohytrate-based anticancer vaccines: Epilope clustering, carrier structure, and adjuvant all influence antibody responses to lewis" conjugates in mice", Proc. Natl. Acad. Sci. U.SA, 98:2542-529, 2001 C82 Kudryashov et al. Cancer immunol. Immunother. 1998, 45, 281-286 C83 Kudryashov, V. et al. (1996) Givoconniguela bumma 15, 243-249 C84 Kudryashov, V. et al. (1996) Givoconniguela bumma 15, 243-249 C65 Kurdika, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzawechis, Science, 1993, 269, 937-944 C68 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunolther. 1997, 45, 10-19									
to vaccination with MUC1-KLH and G03-KLH conjugates*, Vaccine, 19:530-537, 2001 C57 Kim et al. J. Or, Chem. 1995, 60, 7716-7717 C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603 C59 Kjeldsen, T. B. et al. Cancer Res. 1988, 48, 2214-2220 C60 Koeman et al. Tretanedron 1993, 49, 5291-5304 C61 Kudrysshov et al. "Toward optimized carborhydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis* conjugates in mice", Proc. Natl. Acad. Sci. USA, 98:3264-3269, 2001 C62 Kudrysshov et al. Cancer immunol. Immunother, 1998, 45, 281-286 C63 Kudrysshov, V. et al. (1998) Glycoconiugate Journal 15, 243-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kurfika, S. (1996) Vaccine 14, 1239-1242 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzavechis, Science, 1993, 269, 937-944 C68 Livingston et al. Curr. Opin. Immunol. 1992, 4, 624-629 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 Livingston, P. O. et al. Cancer Immunol. Immunolter. 1997, 45, 10-19					and T cell company				
C58 Kim, S. K. et al. (2000) Vaccine 18, 597-603			to vaccination with MUC1-KLH and GD3-KLH conjugates",						
C59 Kjeldsen, T. B. et al. Cancer Res. 1988, 48, 2214-2220 C80 Koeman et al. Tetrahedron 1993, 49, 5291-5304 C81 Kudryashov et al. Toward optimized carbohydrate-based anticancer vaccines: Epitope custefing, cerrier structure, and adjuvant all influence antibody responses to lewis ⁴ conjugates in mice; Proc. Natl. Acad. Sci. USA, 98, 3264-3289, 2001 C82 Kudryashov, V. et al., Cancer Immunol. Immunother. 1998, 45, 281-298 C83 Kudryashov, V. et al., (1999) Glycoconjugates Journal 15, 245-249 C84 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C85 Kwinka, S. (1996) Vaccine 14, 1239-1242 C86 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C87 Lanzawechis, Science, 1993, 269, 937-944 C88 Livingston et al. J. Cancer Res. 1989, 47, 045-7050 C89 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunolter. 1997, 45, 1-9 C72 Livingston, P. O. et al. Cancer Immunol. Immunolter. 1997, 45, 10-19					-				
C60 Koeman et al. Tetrahestron 1993, 49, 5291-5304 C61 Kudryashov et al. 'Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to lewis' conjugates in mice', Proc. Natl. Acad. Sci. USA, 98.2524-3299, 2001 C62 Kudryashov, N. et al. (1999) Glycoconjugate Journal 15, 243-249 C63 Kudryashov, V. et al. (1999) Glycoconjugate Journal 15, 243-249 C64 Kudrik, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kurlikas, S. (1996) Vaccine 14, 1239-1242 C66 Kwore et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzavechis, Science, 1993, 260, 937-944 C68 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Impsu. 1997, 45, 1-9 C72 Livingston, P. O. et al. Cancer Immunol. Immunolther. 1997, 45, 10-19									
C61 Kudryashov et al., 'Toward optimized carbohydrate-based anticancer vaccines: Epilope clustering, carrier structure, and adjuvant all influence antibody responses to lewis' conjugates in mice', Proc. Natl. Acad. Sci. USA, 98:3264-3269, 2001 C62 Kudryashov et al. Cancer Immunol. Immunoleth. 1998, 45, 281-286 C63 Kudryashov, V. et al. (1998) Glycoconjugate Journal 15, 243-249 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 Kurikas, S. (1996) Vaccine 14, 1239-1242 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Larzavechis, Science, 1993, 256, 937-944 C68 Livingston et al. Curr. Opin. Immunol. 1992, 4, 624-629 C69 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunolter. 1997, 45, 1-9 C72 Livingston, P. O. et al. Cancer Immunol. Immunolter. 1997, 45, 10-19									
clustering, carrier structure, and adjuvant all influence antibody responses to lewis ² conjugates in mice ² , Proc. Natl. Acad. Sci. USA, 98.3264-2989, 2001 C62									
C63 Kudriyashov, V. et al. (1998) Glycoconjugate Journal 15, 243-249 C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C65 Kurlika, S. (1998) Vaccine 14, 1239-1242 C66 Kwom et al. J. Am. Chem. Soc. 1998, 120, 12474-12485 C67 Janzawechis, Science, 1993, 269, 937-944 C68 Livingston et al. Curr. Opin. Immunol. 1992, 4, 624-629 C69 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 C70 Livingston et al. J. Cancer Res. 1998, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19 C72 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		C61	clustering, carrier structure, and adjuvant all influence antit						
C64 Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12485		C62	Kudryashov et al. Cancer Immunol. Immunother. 1998, 45	, 281-286					
C65 Kurikka, S. (1996) Vaccine 14, 1239-1242 C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzawchis, Science, 1993, 260, 937-944 C68 Livingston et al. Curr. Opin. Immunol. 1992, 4, 624-629 C69 Livingston et al. J. Cancer Res. 1989, 49, 7045-7050 C70 Livingston et al. J. Cancer (as. 1989, 49, 7045-7050 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 1-9 C72 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		C63_	Kudryashov, V. et al. (1998) Glycoconjugate Journal 15, 24	43-249					
C66 Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599 C67 Lanzavechis, Science, 1993, 260, 937-944 C68 Livingston et al. Curr. Opin. Immunol. 1992, 4, 624-629 C69 Livingston et al. J. Cancer Res. 1993, 49, 7045-7050 C70 Livingston et al. J. Clin. Oncol., 1994, 12, 1036-1044 C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 1-9 C72 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		C64_	Kuduk, S. D. et al. J. Am. Chem. Soc. 1998, 120, 12474-12	2485					
C67		C65	Kurikka, S. (1996) Vaccine 14, 1239-1242						
C68		C66	Kwon et al. J. Am. Chem. Soc. 1998, 120, 1588-1599						
C69		C67	Lanzavechis, Science, 1993, 260, 937-944						
C70		C68 Livingston et al. Curr. Opin. Immunol. 1992, 4, 624-629							
C71 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 1-9 C72 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		C69	Livingston et al. J. Cancer Res. 1989, 49, 7045-7050						
C72 Livingston, P. O. et al. Cancer Immunol. Immunother. 1997, 45, 10-19		C70	Livingston et al. J. Clin. Oncol., 1994, 12, 1036-1044						
ACCEPTANA.		C71 Livingston, P. O. et al. Cancer Immunol, Immunother, 1997, 45, 1-9							
4665073v /Karen A. Canella, Ph.D./ Date Considered 06/07/2010		C72	Livingston, P. O. et al. Cancer Immunol. Immunother. 1997	7, 45, 10-19					
	4665073v 1		/Karen A. Canella, Ph.D./		06/07/2010				

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/728041	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	December 3, 2003	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Samuel J. Danishefsky	
				Art Unit	1643	
(Use as many sheets as necessary)			necessary)	Examiner Name	Karen A. Canella	
Sheet	4	of	5	Attorney Docket Number	2003080-0142(SK-893-B)	

C73	Lloyd et al. (1966) Biochemistry 5, 1489-1501	
C74	Lloyd et al. Am. J. Clin. Path. 1987, 87, 129-139	
C75	Lloyd et al. Cancer Biol. 1991, 2, 421-431	
C76	Lo-Man, R. et al. Cancer Res., 1999, 59, 1520-1524	
C77	Lönn, H. J. Carbohydr. Chem. 1987, 6, 301-306	
C78	M.A. Bernstein et al. Carbohydr. Res. 1980, 78, C1-C3	
C79	Maranduba et al. Carbohydr. Res. 1986, 151, 105-119	
C80	March, Advanced Organic Chemistry, 2nd edition, 1977, page 867	
C81	Marciani, D. J. et al. (2000) Vaccine 18, 3141-3151	
C82	Melani et al. Cancer Res. 1991, 51, 2897-2901	
C83	Merritt et al. J. Am. Chem. Soc. 1994, 116, 5551-5559	
C84	Molrine, D. C. et al. (1995) Annals of International Medicine 123, 828-834	
C85	Mootoo et al. J. Am. Chem. Soc. 1988, 110, 2662-2663	
C86	Mootoo et al. J. Am. Chem. Soc. 1989, 111, 8540-8542	
C87	Mukaiyama et al. Chem. Lett. 1981, 431-432	
C88	Nicolaou et al. "A practical and enantioselective synthesis of glycosphingolipids and related compounds. Total synthesis of Globotriasosylceramide (Gb ₃)", J. Am. Chem. Soc., 110:7910-7912, 1988	
C89	Nicolaou et al. J. Am. Chem. Soc. 1990, 112, 3693-3695	
C90	Nilsson et al. Cancer Res. 1986, 46, 1403-1407	
C91	Nilsson et al. Glycoconjugate J. 1984, 1, 43-49	
C92	Ogata, S. et al. (1994) Cancer Res. 54, 4036-4044	
C93	Orlandi, et al. Clinical Cancer Research, 2007, Vol. 13, pp. 6195-6203	
C94	Pardoll et al. Curr. Opin. Immunol. 1993, 5, 719-725	
C95	Peeters, C. C. et al. (1991) Infect. Immun. 59, 3504-3510	
C96	Qiu et al. Liebigs Ann. Chem. 1992, 217-224	
C97	R.U. Lemieux Chem. Soc. Rev. 1978, 7, 423-452	
C98	Ragupathi et al. "On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines", Proc. Natl. Acad. Sci. USA, 99(21):13699-13704, 2002	
C99	Ragupathi G, et al. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: Synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate J., 15: 217-221, 1998	
C100	Ragupathi, G. et al. Cancer Immunol Immunother 2003, 52, 608-616	
C101	Reddish et al. Glycoconjugate J. 1997, 14, 549-560	
C102	Reithal, Y. J. Am. Chem. Soc. 1952, 74, 4210-4211	
C103	Riddles PW, Blackeley RL, Zerner B Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)a reexamination, Anal Biochem 94: 75-81, 1979	0.0
C104	Rodriguez et al. Aust. J. Chem. 1990, 43, 665-679	
C105	Sabbatini et al. Int. J. Cancer 2000, 87, 79-85	
C106	Sarnaik, S. et al. (1990) Pediatric Infectious Disease 9, 181-186	
C107	Sarvas, H. et al. (1974) Scand. J. Immunol. 3, 455-460	
C108	Schmidt et al. Synthesis 1984, 53-60	
C109	Schmidt, R. R. Synthesis of Glycosides. In Comprehensive organic synthesis; selectivity, strategy and efficiency in modern organic chemistry, Trost, B. M., Fleming, I., Eds.; Pergamon Press: Elmsford, NY, 1991, Vol. 6, pp. 33-64	
		_

4665073v	/Karen A. Canella, Ph.D./	Date Considered	06/07/2010

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/728041	
II.	IFORMATION	I DI	SCLOSURE	Filing Date	December 3, 2003	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Samuel J. Danishefsky	
				Art Unit	1643	
	(Use as many she	eets as	necessary)	Examiner Name	Karen A. Canella	
Sheet	5	of	5	Attorney Docket Number	2003080-0142(SK-893-B)	

С	110	Schwarz, J. B. et al. J. Am. Chem. Soc. 1999 121, 2662-2673	
C	111	Seeberger, P. H. J. Carbohydr. Chem. 2002, 21, 613-643	Т
С	112	Severin et al. Biokhimiya (Moscow), 1973, Vol. 38, pp. 583-588 (abstract only)	
С	113	Sim et al. J. Am. Chem. Soc. 1993, 115, 2260-2267	7
С	114	Springer, G. F. Science 1984, 224, 1198-1206	7
С	115	T. Boon, Int. J. Cancer 1993, 54, 177-180	╗
С		Warren, et al. "Synthetic Glycopeptide-Based Vaccines", In: Topics in Current Chemistry, 2007, Vol. 267, pp. 109-141	
С	117	Williams, L. et al. (2000) Tetrahedron Lett. 41, 9505-9508	7
С	118	Yin et al. Int. J. Cancer, 1996, 65, 406-412	┰
С	119	Zhang, S. et al. (1996) Cancer Research 56, 3315-3319	
С	120	Zhang, S. et al. Int. J. Cancer 1997, 73, 42-49	$\neg \vdash$
С	121	Zhang, S. et al. Int. J. Cancer 1997, 73, 50-56	┰

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

_				
4	665073v	/Karen A. Canella, Ph.D./	Date Considered	/Karen A. Canella, Ph.D./

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.